Safety and Efficacy of Thymosin Beta 4 Ophthalmic Solution in Patients With Dry Eye
This study has been completed.
Information provided by (Responsible Party):
First received: June 29, 2011
Last updated: June 10, 2015
Last verified: December 2012
Thymosin Beta 4 (Tβ4) is a synthetic copy of the naturally-occurring 43-amino acid peptide that is found in a variety of tissues. Tβ4 promotes/accelerates wound repair in dermal, ocular, and cardiac animal models. Two recent pre-clinical evaluations have demonstrated that Tβ4 promotes corneal ocular surface defects healing in animal models of dry eye. RGN-259 (formulation of Tβ4 ophthalmic solution) mechanism of action offers potential to be a product that meets a major unmet medical need in patients with dry eye.
Dry Eye Syndrome
Drug: Thymosin beta 4
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
||A Double-Masked, Randomized, Single-Center Study Evaluating the Safety and Efficacy of 0.1% Tβ4 Ophthalmic Solution Compared to Vehicle on the Signs and Symptoms of Dry Eye in the Controlled Adverse Environment (CAE) Model
Primary Outcome Measures:
- Corneal Staining (Inferior Region) in the Worst Eye in the Controlled Adverse Environment (CAE) Model, Which is a Regulated Environmental Setting Aimed at Exacerbating the Signs and Symptoms of Dry Eye [ Time Frame: Day 29 (end of treatment) ] [ Designated as safety issue: No ]
This is a test that uses orange dye (fluorescein) and a blue light to detect ocular surface defects associated with dry eye. If the test result is normal, the dye remains in the tear film on the surface of the eye and does not adhere to the eye itself. The test is carried out throughout the study till end of treatment Day 29. However, the primary outcome measure itself is determined on Day 29. The scale used to determine the difference in corneal fluorescein staining between RGN-259 and placebo is the ORA scale: 0= no staining (no detectable ocular defect)to 4= confluent staining( severe ocular defect).
Worst eye: In the case that both eyes were eligible for analysis, the worst eye was chosen as the eye with the greater increase of inferior corneal staining from Visit 1 to Visit 2. If both eyes were equal, the eye with greater ocular discomfort at Visit 2 was chosen as the worst eye. If both eyes were equal at Visit 2, then the right eye was chosen as the worst eye.
- Ocular Discomfort in the Worst Eye in the Controlled Adverse Environment(CAE) Model, Which is a Regulated Environmental Setting Aimed at Exacerbating the Signs and Symptoms of Dry Eye. [ Time Frame: Day 29 (end of treatment) ] [ Designated as safety issue: No ]
Dry eye causes ocular discomfort, which is measured using a validated 4-point ORA Scale from the start of the dosing till the end of treatment (Day 29). 0 = no discomfort to 4 = constant discomfort.
If the measurement is lower, then improvement of ocular discomfort can be inferred. The test is carried out throughout the study till end of treatment Day 29. However, the primary outcome measure itself is determined on Day 29.
Worst eye: In the case that both eyes were eligible for analysis, the worst eye was chosen as the eye with the greater increase of inferior corneal staining from Visit 1 to Visit 2. If both eyes were equal, the eye with greater ocular discomfort at Visit 2 was chosen as the worst eye. If both eyes had were equal at Visit 2, then the right eye was chosen as the worst eye.
Secondary Outcome Measures:
- Number of Adverse Events as a Measure of Safety and Tolerability [ Time Frame: Throughout the study till Day 29 ] [ Designated as safety issue: Yes ]
The Adverse events, which will be followed, are: impairment of visual acuity, an increase in intraocular pressure (IOP), and an increase in corneal sensitivity in both eyes.
| Study Start Date:
| Study Completion Date:
| Primary Completion Date:
||October 2011 (Final data collection date for primary outcome measure)
Active Comparator: Thymosin Beta 4
RGN-259 is a preservative-free, sterile eye drop solution containing 0.1% (w/w) Tβ4
Drug: Thymosin beta 4
A preservative-free, sterile eye drop solution containing 0.1% (w/w) Tβ4 for direct instillation into each eye, twice a day (BID) for 28 days.
- RGN-259 (eye drop formulation of Tβ4)
Placebo Comparator: Placebo
The placebo solution is composed of the same excipients as RGN-259 but does not contain Tβ4. The Placebo is identical to the RGN-259 eye drops in color, consistency, and odor.
A preservative-free, sterile eye drop solution containing 0.0% (w/w) Tβ4 for direct instillation into each eye, twice a day (BID) for 28 days.
Other Name: Vehicle Control
Tβ4 promotes wound repair and regeneration in various tissues. In the eye, it promotes corneal epithelial cell migration, decreases inflammation and has anti-apoptotic activities. It up-regulates the gene expression of laminin-5, a major subepithelial adhesion protein, located in the basement membrane region of the cornea, conjunctiva, and important in wound healing. In compassionate-use cases, Tβ4 has demonstrated efficacy in repairing non-healing neurotrophic corneal ulcers and other corneal epithelial wounds. In twenty-four nonclinical toxicology and safety pharmacology studies, the safety of Tβ4 has been demonstrated for its current and planned uses in man. The results of the two recent dry eye murine mouse model studies show that Tβ4 reduced corneal staining more than positive controls and demonstrated statistically significant reduction in staining compared to vehicle control. The results of these studies, in addition to data from compassionate use studies in patients with non-healing corneal surface defects, suggests that Tβ4 has a significant potential to be an important new safe and effective therapeutic in the treatment of dry eye syndrome.
|Ages Eligible for Study:
||18 Years to 85 Years (Adult, Senior)
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
- Have given a written, informed consent.
- Be able and willing to follow instructions, including participation in study assessments, and be present for the required study visits for the duration of the study.
- Have a best corrected visual acuity.
- Have a patient-reported history of dry eye in both eyes.
- Use and/or desire to use an artificial tear substitute for dry eye symptoms within the past 6 months.
- A negative urine pregnancy test if female of childbearing potential.
Have a corneal fluorescein staining score of ≥ 2 in any corneal surface segment in at least one eye at Visit 1.
- Have contraindications to the use of the study drug.
- Have known allergy or sensitivity to the study drug or components thereof.
- Have anterior blepharitis.
- Be diagnosed with an on-going ocular infection or active ocular inflammation.
- Use contact lenses within 1 week before Visit 1 or during the course of the study.
- Have previously had Laser-Assisted in Situ Keratomileusis (LASIK) surgery within 12 months prior to Visit 1.
- Be currently taking any topical ophthalmic prescription or over-the-counter (OTC) solutions, artificial tears, gels, or scrubs and cannot discontinue these medications for the duration of the trial.
- Have used topical ocular cyclosporine within 30 days prior to Visit 1.
- Have had a past or present evidence of malignancy.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01387347
||Gail Torkildsen, MD
||Ora Clinical Research and Development
History of Changes
|Other Study ID Numbers:
|Study First Received:
||June 29, 2011
|Results First Received:
||November 29, 2012
||June 10, 2015
||United States: Food and Drug Administration
Keywords provided by ReGenTree, LLC:
Thymosin beta 4
Dry eye syndrome
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on January 18, 2017
Dry Eye Syndromes
Lacrimal Apparatus Diseases
Peripheral Nervous System Agents
Physiological Effects of Drugs
Respiratory System Agents